PRNewsWire
21 May 2026, 19:45 UTC · 16w ago
Verdict
Headline takes no side. We score MDXG −1.00 across four claims — strongly bearish.
−1.00strongly bearish
More negative than 95% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
MiMedx is lowering its full-year 2026 net sales expectations to a range of $260 to $290 million.
So whatA reduction in full-year guidance typically triggers a valuation markdown and indicates a deteriorating growth outlook.
More negative than 95% of claims this week
MiMedx's first quarter 2026 revenue fell 33.1% year-over-year, missing consensus estimates by $6.8 million.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More negative than 91% of claims this week
Pomerantz LLP is investigating MiMedx for potential securities fraud or other unlawful business practices.
More negative than 86% of claims this week
New Medicare reimbursement policies in the advanced wound care space have caused significant industry disruption and confusion.
More negative than 80% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a securities fraud investigation, missed earnings and revenue estimates, and lowered its full-year sales expectations.
More negative than 78% of ticker scores this week
The company is the subject of an investigation by Pomerantz LLP on behalf of investors.
More negative than 78% of ticker scores this week
The company is the subject of an investigation by Pomerantz LLP on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
22h ago
+20.6%
Price is moving against the score
$4.57 vs $3.79 close before publication (May 20) · not market-adjusted
MDXG chart →
